Skip to main content
Micro-Tech (Nanjing) Co.,Ltd logo

Micro-Tech (Nanjing) Co.,Ltd — Investor Relations & Filings

Ticker · 688029 ISIN · CNE100003MG1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2020-12-02 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688029

About Micro-Tech (Nanjing) Co.,Ltd

https://www.micro-tech.com.cn/

Micro-Tech (Nanjing) Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical devices. The company focuses on providing advanced solutions for gastroenterology, respiratory medicine, and orthopedics. Its product portfolio includes a wide range of endoscopic diagnostic and therapeutic tools such as biopsy forceps, disposable hemoclips, biliary and esophageal stents, and specialized instruments for Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Micro-Tech emphasizes innovation and quality, maintaining international certifications to serve a global healthcare market. By integrating precision engineering with clinical needs, the company aims to improve patient outcomes and procedural efficiency for medical professionals worldwide.

Recent filings

Filing Released Lang Actions
关于向激励对象首次授予限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the initial grant of restricted shares under a stock incentive plan by the company 南微医学科技股份有限公司. It details the grant date, number of shares, recipients, approval procedures, legal and financial advisor opinions, and compliance with regulatory requirements. The content focuses on the company's equity incentive plan and the granting of restricted stock to employees and management. This type of document is a formal announcement about a capital change related to share issuance to employees as part of an incentive plan. It is not a full financial report, audit report, or management discussion, nor is it a regulatory filing or voting result announcement. The document is not a report publication announcement since it contains substantive details about the stock grant. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA).
2020-12-02 Chinese
独立董事关于第二届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting agenda item about the initial grant of restricted stock under a stock incentive plan. It references company law, securities law, listing rules, and the company's articles of association. The content focuses on governance and compliance with legal and regulatory requirements for the stock incentive plan. The document length is short (1005 characters) and it is not a full report but an opinion related to board matters. This fits best under Board/Management Information (MANG) as it concerns board meeting matters and management decisions rather than a full financial report or announcement of voting results.
2020-12-02 Chinese
第二届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of 南微医学科技股份有限公司 regarding the resolution passed in their 13th meeting of the second supervisory board. The content focuses on the approval of a restricted stock incentive plan, including verification of the plan's compliance with relevant laws and regulations, and the approval of the grant date and price. It is a meeting resolution announcement related to management decisions on stock incentives, not a full financial report or earnings release. The document is short (1110 characters) and does not contain financial statements or detailed financial data. It is not a report itself but an announcement of a board/management decision. Therefore, the most appropriate classification is Board/Management Information (MANG).
2020-12-02 Chinese
关于公司2020年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to the company's 2020 restricted stock incentive plan. It details the investigation scope, procedures, and findings about insider trading by persons aware of the incentive plan before its public disclosure. The document is a regulatory announcement about compliance and insider trading checks, not a financial report, earnings release, or management report. It does not contain financial statements or detailed financial data. It is a regulatory filing informing the market about insider trading compliance related to a stock incentive plan.
2020-12-02 Chinese
上海荣正投资咨询股份有限公司关于南微医学科技股份有限公司2020年限制性股票激励计划首次授予事项之独立财务顾问报告
Regulatory Filings
2020-12-02 Chinese
北京金诚同达律师事务所关于南微医学科技股份有限公司2020年限制性股票激励计划授予事项的法律意见书
Regulatory Filings
2020-12-02 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.